United Therapeutics Stock Investor Sentiment
| UTHR Stock | USD 351.17 1.13 0.32% |
Slightly above 55% of United Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding United Therapeutics suggests that many traders are impartial. United Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in United Therapeutics. Many technical investors use United Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Panic Vs Confidence
45
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use United Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward United Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
United Historical Sentiment
Although United Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding United, such as negative comments on social media and news outlets, may cause fear in the market and push United Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of United.
United |
United Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards United Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
United Therapeutics Historical Investor Sentiment
Investor biases related to United Therapeutics' public news can be used to forecast risks associated with an investment in United. The trend in average sentiment can be used to explain how an investor holding United can time the market purely based on public headlines and social activities around United Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
United Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for United Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average United Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on United Therapeutics.
Far too much social signal, news, headlines, and media speculation about United Therapeutics that are available to investors today. That information is available publicly through United media outlets and privately through word of mouth or via United internal channels. However, regardless of the origin, that massive amount of United data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of United Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of United Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to United Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive United Therapeutics alpha.
United Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 237 shares by Michael Benkowitz of United Therapeutics at 362.0202 subject to Rule 16b-3 | 11/18/2024 |
2 | Disposition of 402 shares by Michael Benkowitz of United Therapeutics at 374.3507 subject to Rule 16b-3 | 12/06/2024 |
3 | 1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today | 12/11/2024 |
4 | Disposition of 15000 shares by Sullivan Louis W of United Therapeutics at 175.43 subject to Rule 16b-3 | 12/18/2024 |
5 | Disposition of 1851 shares by Sullivan Louis W of United Therapeutics subject to Rule 16b-3 | 12/19/2024 |
6 | Why United Therapeutics is a Top Value Stock for the Long-Term | 12/23/2024 |
7 | Disposition of 2500 shares by Michael Benkowitz of United Therapeutics at 111.0 subject to Rule 16b-3 | 12/26/2024 |
8 | Investing in United Therapeutics five years ago would have delivered you a 316 percent gain | 12/30/2024 |
9 | OS Therapies Announces Closing of 6 Million Private Placement | 12/31/2024 |
10 | Disposition of 7700 shares by Mahon Paul A of United Therapeutics at 163.3 subject to Rule 16b-3 | 01/02/2025 |
11 | Insider Selling United Therapeutics Co. Director Sells 90,721.35 in Stock | 01/03/2025 |
12 | United Therapeutics Corp to Present at J.P. Morgan Healthcare Conference | 01/06/2025 |
13 | UTHR vs. STVN Which Stock Is the Better Value Option | 01/08/2025 |
14 | Heres Why United Therapeutics is a Strong Growth Stock | 01/10/2025 |
15 | Disposition of 600 shares by Michael Benkowitz of United Therapeutics at 367.8917 subject to Rule 16b-3 | 01/13/2025 |
16 | OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resecte... | 01/15/2025 |
17 | Disposition of 100 shares by Michael Benkowitz of United Therapeutics at 375.22 subject to Rule 16b-3 | 01/27/2025 |
18 | KBC Group NV Purchases 7,169 Shares of United Therapeutics Co. - MarketBeat | 01/28/2025 |
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.